Description: KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. The company was founded in 2006 and is headquartered in Celebration, Florida.
Home Page: kempharm.com
KMPH Technical Analysis
1180 Celebration Boulevard
Celebration,
FL
34747
United States
Phone:
321 939 3416
Officers
| Name | Title |
|---|---|
| Mr. Richard W. Pascoe | Exec. Chairman |
| Dr. Travis C. Mickle Ph.D. | Co-Founder, Pres, CEO & Director |
| Ms. Christal M. M. Mickle M.A. | Co-Founder and Sr. VP of Operations & Product Devel. |
| Mr. R. LaDuane Clifton CPA | CFO, Sec. & Treasurer |
| Dr. Sven Guenther | Exec. VP of R&D |
| Ms. Nichol L. Ochsner | VP of Investor Relations & Corp. Communications |
| Mr. Timothy J. Sangiovanni CPA | VP & Corp. Controller |
| Dr. Andrew Barrett | VP of Scientific Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 263.1579 |
|---|---|
| Trailing PE: | 16.6 |
| Price-to-Book MRQ: | 1.6922 |
| Price-to-Sales TTM: | 14.1611 |
| IPO Date: | 2015-04-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 24 |